Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> StudyJoong‐Won Park, Morris Sherman, Minshan Chen et al.|Liver International|2015Cited by 1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Shukui Qin et al.|Journal of Clinical Oncology|2013Cited by 775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Thomas Decaens et al.|Journal of Clinical Oncology|2013Cited by 596
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Anthony B. El-Khoueiry, Marina Tschaika et al.|Journal of Hepatology|2020Cited by 421
The role of hepatic resection in the treatment of hepatocellular cancerSasan Roayaie, Morris Sherman, Ghalib Jibara et al.|Hepatology|2015Cited by 415